Molecule Details
InChIKeyUUDPUQDMSHQSKH-NSHDSACASA-N
Compound NameElzovantinib
Canonical SMILESCCN1Cc2c(ccc(F)c2C#N)O[C@@H](C)CNC(=O)c2c(N)nn3ccc1nc23
Clinical Status Data-mined Candidate
Targets (Human+Pathogen)3
Pfam Stratification Homologous
Avg pChEMBL9.15
SourceChEMBL;BindingDB
2D Structure
2D structure
Activity Profile
DrugBank Annotations
DrugBank ID DB18918
Drug NameElzovantinib
CAS Number2271119-26-5
Groups investigational
ATC Codes nan
DescriptionElzovantinib is under investigation in clinical trial NCT03993873 (Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET).

Cross-references: ChemSpider: 72380105 PDB: IYC
Target Activities (3)
Target Gene Organism Category Pfam pChEMBL Type Source
P08581 MET Homo sapiens Human PF07714 PF01437 PF01403 PF01833 9.3 IC50 ChEMBL;BindingDB
P07333 CSF1R Homo sapiens Human PF00047 PF25305 PF07714 9.1 IC50 ChEMBL;BindingDB
P12931 SRC Homo sapiens Human PF07714 PF00017 PF00018 9.0 IC50 ChEMBL;BindingDB
DrugBank Target Actions (3)
Target Gene Target Name Action Type
P07333 CSF1R Macrophage colony-stimulating factor 1 receptor inhibitor targets
P08581 MET Hepatocyte growth factor receptor inhibitor targets
P12931 SRC Proto-oncogene tyrosine-protein kinase Src inhibitor targets